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ABSTRACT 
The purpose of this review is to summarize the recent literature focusing on intravenous (IV) 
administration of commonly used anesthetics, including midazolam, pentobarbital/ thiopental, propofol, 
and ketamine in the treatment of status epilepticus (SE). Anesthetics should be reserved as third-line 
therapy for the treatment of SE when benzodiazepines and other second-line agents fail to terminate the 
seizure. We have reviewed the literature related to the treatment of status epilepticus, refractory status 
epilepticus, super-refractory status epilepticus, anesthetics, midazolam, pentobarbital/thiopental, propofol, 
and ketamine. This paper focuses on the pharmacology, dosages, major side effects, and clinical use of IV 
anesthetics in the treatment of SE with an emphasis on the developing literature supporting the use of 
ketamine for this indication. Based on the available literature, we propose recommendations for third-line 
agent selection in the management of SE. 
INTRODUCTION 
Anesthetics (pentobarbital/thiopental/phenobarbital, propofol, and ketamine) and continuous infusion 
midazolam are widely used for seizures that do not respond to initial emergent benzodiazepines to curtail 
seizures and initiation of second-line antiepileptic drugs (AED). Status epilepticus (SE) is defined as 5 
minute or more of continuous or intermittent (without recovery between seizures), clinical and/or 
electrographic seizure activity.1 SE can be either convulsive SE (convulsions with rhythmic jerking 
movement) or non-convulsive SE (seizure activity on electroencephalography (EEG) without 
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convulsions).1 If SE does not respond to intravenous (IV) benzodiazepines and a second-line AED 
(including IV fosphenytoin, phenytoin, valproic acid, levetiracetam, or phenobarbital), then the patient has 
progressed to refractory status epilepticus (RSE), which requires further treatment with anesthetics. 
Super-RSE occurs when RSE does not respond to continuous infusion IV anesthetics.2 Since anesthetics 
are used in the treatment of refractory SE after administration of benzodiazepines and second-line 
antiepileptics, they are commonly called third-line antiepileptics. Continuous EEG monitoring should be 
utilized in the diagnosis and treatment of the condition as well as the adjustment of the medications.3
SE is a time-sensitive emergency that requires immediate treatment.4 Rapid cessation of SE is necessary as 
it is shown in multiple studies that prolongation of SE can make the condition more resistant to treatment 
and complicates with neurological and systemic adverse outcomes.5 Therefore, anesthetics should be 
readily available in any clinical setting where SE is managed, as 40% of patients with SE do not respond to 
first-line drug therapy and will require additional treatment2 and 43% of patients will progress to RSE.6 IV 
anesthetic drugs should be used to induce a therapeutic coma as the next level of the treatment of SE. On 
average, cessation of SE requires three AEDs.7
Despite extensive use of anesthetics in the treatment of SE, there are not any completed, 
randomized-controlled studies that compare safety and efficacy between anesthetic groups.8 Prospective 
studies showed that after controlling for confounders, anesthetic use is associated with poor outcome 
[death, worse Glasgow Outcome Score (GOS)]9, increased risk of disability, infections, and extended 
hospitalization in the treatment of SE.10 These findings may also reflect the medical complications of 
extended SE, as this group is more likely to have a therapeutic coma.11 Additionally, systematic reviews 
have not demonstrated superior efficacy of one anesthetic over another in the management of SE.12,13
Therefore, anesthetic selection should be based on adverse effect profile and patient-specific factors.14 
This review compares the most commonly used anesthetics in the setting of RSE, including propofol, 
pentobarbital/thiopental, and ketamine, as well as IV continuous infusion midazolam. The use of inhaled 
anesthetics are typically impractical15 and outside the scope of this paper. A literature search was 
performed on Pubmed with abstracts or titles including keywords “status epilepticus” and “anesthetics” or 
“midazolam” or “propofol” or “pentobarbital” or “phenobarbital” or “thiopental” or “ketamine.” Out of 
321 search results, 170 articles were dated between 1985-2018, written in the English language, and 
deemed to be related to the treatment of RSE. 57 citations were determined to include unique data for 
review and discussion. The same search with keywords was done at ClinicalTrials.gov and related trials 
were included. 
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Midazolam for Refractory Status Epilepticus 
 
Midazolam is the single most commonly used medication to control SE.16 Gamma aminobutyric acid 
(GABA) secretion from the substantia nigra (SN) is a critical element in seizure control17, and midazolam 
is a benzodiazepine that enhances the inhibitory effect of GABA by binding post-synaptic 
GABAA receptors.4 Midazolam can be administered through intramuscular, buccal, or intranasal routes 
which is beneficial in the pre-hospital setting when IV access may not be available.18 However, inpatient 
administration of the drug for SE is generally limited to IV bolus and infusion which allows for rapid onset 
of action and dose titration. While the half-life of midazolam is considered to be short (3 h), sedative 
effects may be prolonged due to the active metabolite α-hydroxy-midazolam. Patients with obesity, heart 
failure, cirrhosis, advanced age, or renal failure, or those who have received long durations of therapy, are 
most likely to experience sustained sedative effects [up to 50 hour(h)] after drug discontinuation.19 
In RSE, midazolam is initiated with a bolus dose of 0.05 to 0.2 milligram/kilogram (mg/kg) given at a max 
rate of 2-4 mg/minuteand followed by continuous IV infusion at 0.1 mg/kg/h. If seizures are not controlled 
within 15 minute or there is a breakthrough seizure, an additional IV bolus dose should be administered 
with a concomitant infusion titration as outlined in Table 1 in the appeddix.1. Once seizures have been 
controlled for 24-48 hours, the midazolam infusion can be tapered down at a rate of 1 mg/h every 12 
hours20, although more rapid titration protocols have been studied with dose reductions occurring every 
4-6 hours.21 Ultimately, continuous EEG monitoring and patient response should guide titration off 
midazolam infusion. Patients are generally considered to have super-RSE when seizures cannot be 
controlled with an infusion rate of 2 mg/kg/h, although infusions up to 2.9 mg/kg/h have been studied for 
RSE. Once super-RSE is established, an alternative agent should be selected. 
A retrospective cohort study by Fernandez et al. demonstrated that a treatment protocol with high-dose 
continuous IV infusion midazolam at doses up to 2.9 mg/kg/h was associated with a significant reduction 
in withdrawal seizure rate within 48 hours of midazolam discontinuation (15% vs. 64%) and discharge 
mortality (40% vs. 62%) when compared to a traditional, low-dose protocol with a maximum infusion rate 
of 0.4 mg/kg/h.21 Patients in the high-dose cohort were more likely to develop hypotension requiring 
vasopressor administration (53%) compared to the low-dose cohort (32%), but these rates are comparable 
to other IV anesthetics for RSE including propofol and pentobarbital and did not increase the risk of 
mortality.8,21,22 No other increased adverse events associated with high-dose infusion were noted by the 
authors.21 
Although there is variable reported efficacy for midazolam in RSE ranging from 25%20to 86%23, 
midazolam appears to be the safest with less metabolic and cardiovascular side effects when compared to 
other anesthetics.2 In addition to hypotension, other adverse reactions include bradycardia, inotropic 
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support requirements, and dyselectrolytemia.20 Tachyphylaxis may develop early, even within the first day 
of continuous infusion administration, and will necessitate progressive increases in dose to achieve the 
same effect18. 
 
Anesthetics for Refractory Status Epilepticus 
 
 
Propofol. Propofol (2,6-diisopropyl phenol) is a GABAA receptor agonist and N-methyl-D-aspartate 
(NMDA) receptor antagonist used in the treatment of RSE. Due to its effects of decreasing intracranial 
pressure and cerebral metabolism, as well as the favorable pharmacokinetic profile, propofol has been 
widely utilized in neurocritical care setting24 and is the second most commonly used third-line line AED 
for RSE.16 Propofol is highly lipophilic and acts rapidly with an onset of action of 30 seconds. While there 
are no active metabolites and the half-life is generally considered short (40 minute), the terminal half-life 
may be up to 7 h and can be longer in elderly patients and those who received prolonged infusions (10 
days or longer) due to the increased volume of distribution.19,25 Genetic polymorphisms of the 
metabolizing enzymes and receptors for propofol have been proposed to impact the variation in clinical 
response to therapy. However, no significant correlation between cytochrome P450 genotypes, plasma 
propofol concentration, and loss of consciousness have been determined.26 Age, gender, ethnicity, anxiety, 
the use and abuse of drugs, and other genetic factors may contribute to propofol response.26 
Propofol should be initiated loading dose of 1 to 3 mg/kg given as a slow IV push followed by a 
continuous infusion starting at 20 microgram(mcg)/kg/ minute. 1 to 2 mg/kg serial boluses may be 
repeated every 3-5 minute until seizures on EEG are suppressed.6 For breakthrough SE, increase rate by 5 
to 10 mcg/kg/ minute every 5 minute or administer a 1 mg/kg bolus. Continuous infusion rates required to 
maintain burst suppression vary widely, ranging from 30 to 200 mcg/kg/ minute.1 It has been reported that 
nearly half of patients receiving propofol for RSE develop breakthrough seizures during the weaning 
phase.22 Patients should be monitored with continuous EEG while tapering off propofol. Tapering 
schedules of 20 percent every 3 hours have been proposed6, as described in Table 1. 
Despite the vast clinical experience with propofol since its FDA approval as a sedative in the late 1980s,25 
efficacy data in RSE is limited.24 A recent, comparative study showed equal efficacy of propofol and 
midazolam in attaining seizure control in a small group of patients with RSE (n=23).20 There was a 
significant reduction in hospital length of stay with propofol compared to midazolam (11 vs. 20.5 days, 
p=0.02), but also a non-statistically significant increase in mortality (72.7% vs. 58.3%, p=0.6).20 
Loading doses may precipitate hypotension, and caution should be utilized in patients with hemodynamic 
instability. Use caution when administering high doses (5 mg/kg/h) for extended periods of time (i.e., 
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greater than 48 h),27 as this increases the risk of propofol-related infusion syndrome (PRIS). PRIS is a rare 
but significant complication of mitochondrial toxicity27 manifested by metabolic acidosis, 
rhabdomyolysis, hyperkalemia, hepatomegaly, renal failure, hyperlipidemia, arrhythmias, and rapidly 
progressive heart failure.27,28 Monitoring for bicarbonate, creatine kinase, potassium, liver function tests, 
urea/creatinine, and triglyceride levels are reasonable for long term administration of propofol. The risk 
for PRIS is higher in the pediatric population.29 
 
Pentobarbital/Thiopental and Phenobarbital. Barbiturates are GABAA receptor agonists that exert 
sedative, hypnotic, and anticonvulsant effects through the depression of the sensory cortex and motor 
activity.19 Since thiopental is no longer available in the United States, pentobarbital is the gold standard for 
reducing cerebral metabolism and induction of barbiturate coma in RSE that is non-responsive to 
midazolam or propofol. Since pentobarbital reduces intracranial pressure, it is the preferred agent for SE 
in the setting of traumatic brain injury and large ischemic strokes.30 While phenobarbital is also a 
barbiturate, its role is primarily for termination of early phase seizures that have not yet progressed to SE.2 
However, there is more recent interest in its use for focal RSE and should be considered during the initial 
or second therapy phases (15-20 mg/kg IV push), especially when there is impairment of consciousness 
due to ongoing focal seizures.24,31 
Both thiopental and pentobarbital are highly lipophilic, contributing to short onsets of action of 30 seconds 
and 3-5 minute, respectively. Although they exhibit zero-order kinetics and are hepatically metabolized to 
mostly inactive metabolites, there is the potential for prolonged durations of action (half-life up to 50 h) 
due to extensive distribution in the body with deposition in the fatty tissue.19 
Pentobarbital is initiated with a 5 to 15 mg/kg loading dose administered at a rate of less than 50 mg/ 
minute, followed by continuous infusion 0.5 to 5 mg/kg/h. For breakthrough SE, 5 mg/kg IV bolus can be 
administered, with infusion rate increases of 0.5 to 1 mg/kg/h every 12 h.1 Once a 24-48 h seizure-free 
interval is achieved, the infusion can be tapered off by 20 percent every 3 hours. Thiopental dosing is 
described in Table 1. In general, therapeutic drug monitoring is not indicated for pentobarbital or 
thiopental dose adjustments. 
The systematic review by Claassen et al. compared the efficacy and safety of midazolam, propofol, and 
pentobarbital in RSE. While the phenobarbital group had a shorter median duration of RSE (13 h) 
compared to the midazolam group (30 h), significantly less treatment failure, breakthrough seizures, and 
need to change to an alternative continuous infusion AED, there was a significantly higher rate of 
hypotension requiring vasopressor therapy.22 
Barbiturates are potent AEDs that can quickly stop seizures but at the expense of high risk for adverse 
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events, including hypotension requiring vasoactive drugs to control blood pressure, prolonged mechanical 
ventilation, and inadequate temperature regulation.6,19,32 Although anesthetic use itself in SE increases 
infection risk, the risk is the highest among patients utilizing barbiturate therapy.13,33 With prolonged 
mechanical ventilation, there is also an increased risk for ventilator-associated pneumonia.6 One cohort 
study showed a high incidence of urinary tract infection (13%), deep venous thrombosis (10%), and ileus 
(10%) in patients who received continuous infusion pentobarbital.34 Transient propylene glycol 
intoxication was also described.34. Drug reaction with eosinophilia and systemic symptom (DRESS) is a 
serious, life-threatening, but rare adverse effect that has been described with pentobarbital. There is at least 
one report of successful desensitization to phenobarbital maintenance therapy.35 
 
Ketamine. It is shown in animal studies that as GABA receptors decrease during SE, excitatory 
N-methyl-d-aspartate (NMDA) receptors increase.36 Ketamine is primarily a noncompetitive NMDA 
receptor antagonist, which has been utilized as an add-on therapy in RSE when patients fail to respond to 
other third-line agents.16,18,37 It may also be useful in substance abuse-related RSE.38 Ketamine interacts 
with several other receptors, including cholinergic (bronchodilatation, muscle relaxant), opioid (analgesia), 
glutamate (sedation, antihyperalgesic, anticonvulsant, neuroprotection), GABA (inhibition of 
neurotransmission), catecholamine (stimulation of cardiovascular function) and adenosine 
(immunomodulation).39 The molecule is extensively distributed in the body due to the large volume of 
distribution due to high lipid and water solubility.40 It has a rapid onset of action (30 seconds) and is 
converted to the active metabolite norketamine by the cytochrome P3A418 which accounts for a terminal 
beta half-life of 2-3 h. 
Although ketamine is a standard medication for anesthesia induction, there is no definitive protocol for its 
use in SE.41 Initial bolus doses of 1-2 mg/kg IV push given every 3-5 minute until there is the cessation of 
seizure are recommended, followed by the initiation of IV continuous infusion. Significant variations in 
dosing have been described with most infusions ranging from 0.0075 to 10.5 mg/kg/h.41 However, a more 
recent review described typical ketamine dosing for RSE as 1-5 mg/kg IV push,42, which is similar to 
anesthesia induction doses, followed by continuous infusions of 0.07-15 mg/kg/h.18,42 Ketamine can be 
utilized in combination with another anesthetic and has been shown to have synergistic effects with 
benzodiazepines and propofol.18,43,44 Duration of ketamine infusion has been described ranging from 6 h 
to 29 days.40 
Regardless of the SE type, convulsive vs. non-convulsive, ketamine has been demonstrated to be twice as 
effective if administered early in RSE (3 days) compared to longer duration RSE (26.5 days).40 Despite 
this, its typical usage is often delayed as long as 3-9 days after seizure onset.45 An additional area of 
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interest is with early ketamine administration, as this has been shown to avoid endotracheal intubation in 
several cases.40 Given its efficacy and safety profile, as well as the potential to reduce the need for 
intubation, ketamine may be considered as the first anesthetic choice for specific situations and in the out 
of hospital setting.40 This may be an important area for future research because intubation is a negative 
prognostic factor for SE.46 
 
Available literature supporting the use of ketamine in RSE is primarily limited to observational and 
retrospective studies.40 A recent systematic review demonstrated excellent outcomes in SE management, 
with 75% of studies reporting moderate or complete seizure control in adult patients.41 There is 
developing interest in using ketamine due to the potential neuroprotective effects through NMDA receptor 
blocking,47, anti-inflammatory properties, optimization of peripheral circulation, and balancing transport 
and consumption of oxygen.39 There are two ongoing clinical trials of ketamine in RSE which should 
provide more robust data to support its use for this indication: Ketamine in Refractory Convulsive Status 
Epilepticus (KETASER01), ClinicalTrials.gov Identifier: NCT02431663; and Efficacy of Ketamine 
Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus, 
ClinicalTrials.gov Identifier: NCT03115489. Interestingly, neurointensivists have more readily adopted 
the use of ketamine for RSE than the other physician groups.48 An area for further research would be with 
concomitant use of IV and enteral ketamine as case reports in RSE have shown a reduction in seizure 
recurrence and shortened the duration of stay in the ICU.49 Additionally, ketamine may have a niche in the 
setting of SE due to encephalitis due to its potent anti-inflammatory effect.50 
 
Since ketamine is mostly used for short intervals for anesthesia induction, there is not much information 
on complications related to long term or high dose administration.41 Ketamine induces a positive, 
sympathetic response. Use is cautioned in patients with coronary artery disease and/or cardiomyopathy as 
it may induce hypertension40,51 tachyarrhythmias, including atrial fibrillation51, even cardiac arrest.52 
Patients with subarachnoid hemorrhage (SAH) who receive ketamine have enhanced sympathomimetic 
effects and may develop life-threatening arrhythmias and cardiac arrest. Additionally, ketamine has been 
shown to cause hypotension as some large clinical series have demonstrated the need for increased 
vasopressor requirements when compared to other anesthetics40,51–53. Rarely, severe metabolic acidosis 
has been reported with doses of 4-4.5 mg/kg/hr in combination with midazolam infusion.41 
 
Additionally, encephalopathy, confusion, agitation, or psychosis can be seen even after discontinuation of 
ketamine.18,51 Cerebellar atrophy has been reported with ketamine use.54 Increases in oral and bronchial 
secretions can be prevented by administering anticholinergics.51 
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SE should preferably be managed or co-managed by a specialist since optimizing treatment will decrease 
mortality and treatment complications. Induction of coma with anesthetics should be promptly initiated in 
an appropriate clinical setting as the cessation of SE is compatible with a decrease in overall morbidity, 
pharmacoresistance, neuronal injury.2 When initial and subsequent treatments are delayed, resistance to 
AEDs increases through cellular mechanisms.4 Midazolam and propofol are usually used as initial 
anesthetics, while pentobarbital is often reserved for RSE unresponsive to these drugs.5 Ketamine may be 
preferable as adjunctive therapy in the later stages of RSE. 
An initial loading dose of anesthetics should be administered, followed by continuous IV infusion. If SE 
does not subside, another bolus dose of the same anesthetic can be administered. If the seizures are 
recurring greater than 3 times within 15 minutes or do not stop within 15 minutes, the dosages should be 
increased to the next level.20 When seizures are not controlled at the maximum anesthetic infusion rate, 
RSE is considered to be super RSE, and another anesthetic should be added.20 
Dosing of anesthetics should be titrated to the cessation of electrographic seizures or burst suppression 
with a goal inter-burst interval of 10 seconds.55 EEG recordings should be sustained for 24-48 h before a 
trial of withdrawal of anesthetics.1 New data also suggest that “the amount of epileptic activity in the 
burst” is also predictive of the success of the weaning of anesthetics.56 However, ketamine may not fit 
these typical EEG patterns. Diffuse slowing and diffuse beta activity patterns can also be targeted to 
achieve along with the burst-suppression.40 During this transition off of continuous IV infusion anesthetic, 
continuous EEG is essential to monitor. If continuous EEG is not available at a facility, the patient may 
need to be transferred to a higher level of care so that anesthetic can be safely titrated.1 Although dose 
adjustment, according to electrographic seizure activity, is recommended to achieve the treatment goal, 
this may be associated with more treatment-related complications.18 
Management of withdrawing anesthetics is a delicate matter, as complications may arise during titration. 
Anesthetics are adjunctive therapies and must be given with second-line AEDs, which are throughout RSE 
and post-RSE treatment. Non-sedating AEDs should be utilized during anesthetic withdrawal episodes 
with careful monitoring and management. Some brief breakthrough seizures may occur during anesthetic 
withdrawal, but rather than increasing the anesthetic dose,3 an extra bolus dose can be given to terminate 
the seizure.57 However, if short or brief seizures progress to SE, anesthetic tapering should be stopped and 
increased to the prior, effective dose. Another 24-48 h period of electrographic stability should be achieved 
before attempting an anesthetic withdrawal.20 If the patient is not seizure-free during these withdrawal 
trials, the subsequent cycle will need to be extended to greater than 48 hours.18 If tapering of the anesthetic 
fails more than four times, this is considered the failure of the anesthetic drug, and an alternative agent 
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The use of anesthetics is a mainstay in the treatment of RSE since they provide rapid clinical response and 
seizure control. The availability of continuous EEG monitoring will provide guidance to titrate anesthetics 
and decide when to taper anesthetics safely. Although anesthetics have been shown to terminate seizures 
effectively, there is an increased risk of prolonged intensive care unit stay, ventilator treatment, and 
complications related to the anesthetics themselves. 
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APPENDIX 
 
Table 1. Pharmacologic comparison of continuous infusion midazolam and anesthetic agents for status epilepticus 
 
 Mechanism of 
action 
Pharmacokinetics Dosing Major adverse events Clinical considerations 
Midazolam 
 
[19, 1, 21, 46] 
Enhances the 
inhibitory effect of 








 Onset: 3-5 minute 
 Vd: 1-3 L/kg 
 Metabolism: 
Hepatic, CYP3A4 
to active metabolite 
α-hydroxy-
midazolam 
 Half-life: 3 h (range 
1.8-6.4 h), up to 20-
50 h with prolonged 
continuous 
infusions (days-
weeks of therapy) 





 LD: 0.05 to 
0.2 mg/kg 
given at a max 
rate 2-4 mg/ 
minute 
 Infusion rate: 
0.1 mg/kg/h 
 Titrate by: 
0.05-0.1 
mg/kg/h every 

























 High-dose infusion rates up to 
2.9 mg/kg/h may be preferred to  
traditional, low-dose infusion 
rates of 0.4 mg/kg/h due to 
significant reduction in 
withdrawal seizure rate and 
discharge mortality 
 Active metabolite may result in 
prolonged sedative effects 
especially in patients with 
obesity, heart failure, cirrhosis, 
advanced age, renal failure, or 
those who have received long 
durations of therapy 
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 Onset: 30 seconds 
 Vd: 2-10 L/kg 
(large due to 
lipophilicity) and 
may be up to 60 
L/kg with prolonged 
infusions (10 days) 
 Metabolism: hepatic 




 Half-life: initial 40 
minute, terminal 4-
7 h  
 Elimination: Urine 
 LD: 1-3 mg/kg 
 Infusion rate: 20 
mcg/kg/ minute 
 Titrate by: 5-10 
mcg/kg/min every 5 
minute, max rate 200 
mcg/kg/ minute 
 Breakthrough 
seizures: 1-2 mg/kg 
bolus, plus infusion 
titration to achieve 
burst suppression 
 Taper: 20 percent 








 Cardiac failure 
 Rhabdomyolysis 
 Metabolic acidosis 
 Propofol related 
infusion syndrome 
(PRIS) 
 The use of propofol for RSE is 
associated with reduced hospital 
length of stay compared to low-
dose midazolam infusion. 
However, there was also a non-
statistically significant increase 
in mortality [27] 
 Lipid emulsion vehicle 




Yilmaz et al.: Anesthetic Use In Status Epilepticus: A Concise Review
Published by Rowan Digital Works, 2020
Pentobarbital 
 
[6, 12, 1, 19, 
22, 31] 
Barbiturates are 






the sensory cortex 










 Onset: 3-5 minute 
 Vd: 1 L/kg 




 Half-life: 22 h 
(range 15-50 h) 
 Elimination: Urine 
 LD: 5-15 mg/kg, may 
give additional 5-10 
mg/kg; administer at 
rates ≤50 mg/ minute 
 Infusion rate: 0.5-5 
mg/kg/h 
 Titrate by: 0.5-1 
mg/kg/h every 12 h 
 Breakthrough 
seizures: 5 mg/kg 
bolus 
 Taper: 20 percent 






 Cardiac depression 
 Ileus 





 Cardiac depression 
 Phenobarbital is associated with 
a shorter median duration of 
RSE, less treatment failure, 
breakthrough seizures, and a 
need to change to alternative 
AED compared to midazolam 
infusion. However, this may be 
outweighed by an increased risk 
of adverse effects.  
 Efficacy may be outweighed by 
increased adverse reactions/side 
effects 
 Contains propylene glycol, 
monitor osmolar gap for 
propylene glycol toxicity 
  
Thiopental  Onset: 30-40 
seconds 
 Vd: 1.7-2.5 L/kg 
 Metabolism: hepatic 




 Half-life: 3-8 h, up 
to 10-12 h with 
prolonged 
administration 
 Elimination: Urine 
LD: 5 mg/kg, may 
give additional 1-2 
mg/kg to achieve burst 
suppression 
Infusion rate: 0.5-5 
mg/kg/h 
Titrate by: 0.5-1 
mg/kg/h every 12 h 
Breakthrough 




















 Onset: 30 seconds 
 Vd: 2.4 L/kg  
 Metabolism: 
CYP3A4 to active 
norketamine 
 Half-life: alpha 10-
15 minute, beta 2-3 
h 
 Elimination: Urine 
 
 LD: 1-3 mg/kg every 
3-5 minute until 
cessation of seizure 
(max 5 mg/kg) 
 Infusion rate: 0.7-15 
mg/kg/hr 
 Taper: 20 percent 
reduction every 3 h 
 
 
 Hypertension, caution 
in patients with 
coronary artery 





 Intracranial pressure 
increases 
 Agitation, confusion, 
and psychosis may be 
observed even after 
drug discontinued 
 Hypersalivation 
 Severe metabolic 
acidosis when given 
in combination with 
midazolam 
 Should be used in combination 
with another anesthetic, 
particularly one with GABA 
activity, most commonly with 
midazolam 
 Consider as add-on therapy when 
RSE fail to respond to other 
third-line agents 
 May consider in early RSE as it 
has been shown to avoid 
endotracheal intubation 
 
*LD=loading dose, cEEG=continuous EEG, Vd=volume of distribution, L=Liter, kcal/mL= kilocalorie/milliliter 
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